Despite several attempts with a variety of pharmacological interventions, including vasodilators, diuretics, analgesics, antioxidants, cholesterol-lowering and anti-inflammatory drugs, no successful interventions have been identified that prevent CSA-AKI.7 8 However, sodium-glucose cotransporter-2 (SGLT2) inhibitors are promising new drugs to prevent CSA-AKI. Here, SLC5A2 is linked to chromosome-type aberration frequency.